Logo
x

Search

Subscribe Now

First Therapy

Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyroid Cancers

Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyr...

  • May 11, 2020
AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas

AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neuro...

  • April 13, 2020
Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

  • March 6, 2020
Pfizer's Vyndaqel (tafamidis- 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in the EU

Pfizer's Vyndaqel (tafamidis- 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in t...

  • February 18, 2020
Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

  • January 24, 2020
Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

  • January 22, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.